Company intelligence / Profile preview

Scite Pharma

Copenhagen, Denmark

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Scite Pharma is a clinical-stage biotechnology company based in Denmark focused on developing innovative topical treatments for chronic pain. The company's lead program, SCP-1, is a proprietary topical formulation of a TRPA1 antagonist designed to provide localized relief for neuropathic pain conditions. By targeting peripheral pain mechanisms, Scite Pharma aims to offer effective analgesia with reduced systemic side effects compared to oral medications. The company is currently advancing SCP-1 through Phase 2 clinical trials for indications such as post-herpetic neuralgia and diabetic peripheral neuropathy.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Scite Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scite Pharma.

Explore the full profile